Japan has intractable disease (so called 'nanbyo' in Japanese) surveillance
and subsidy program. Intractable disease is defined as rare and chronically
progressive diseases, which cause patients disability and social and
financial burden. eg. Systemic lupus erythematosus, dermatomyositis,
myasthenia gravis, ulcerative colitis and so on.
To get more outcome from this program, data repository will be reconstructed
with archetype technology. We are now modeling the clinical research forms
and making archetypes. This is the first practical step of the openEHR in Japan.
Shinji KOBAYASHI